Viewing StudyNCT06211764

Home Icon Home Search Icon Search Alerts Icon Stocks Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs eRecord Icon eRecord
Main Search All Studies All Organizations Report Bug
View Study With Definitions
Ignite Creation Date: 2024-05-06 @ 7:59 PM
Last Modification Date: 2024-10-26 @ 3:18 PM
Study NCT ID: NCT06211764
Status: RECRUITING
Last Update Posted: 2024-06-20
First Post: 2024-01-09
Brief Title: A Study of TAR-200 Versus Intravesical Chemotherapy in Participants With Recurrent High-Risk Non-Muscle-Invasive Bladder Cancer HR-NMIBC After Bacillus Calmette-Guérin BCG
Sponsor: Janssen Research Development LLC
Organization: Janssen Research Development LLC
Overview Dates Organization Conditions Design Enrollment Locations Outcomes

Conditions & Keywords Data

Conditions:
Name
Non-Muscle Invasive Bladder Neoplasms
Keywords: